Acesis Holdings Corporation (ACSB)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	80.61M
Revenue (ttm)	n/a
Net Income	-1.55M
EPS	-0.10
Shares Out	16.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ACSB

Acesis Holdings Corporation together with its wholly-owned subsidiaries, is an emerging, pre-phase 1 (first-in-man “FIM”) clinical, biotechnology company focused on men’s health. Since the incorporation of ABI in the State of Colorado on March 11, 2015, we have been developing novel treatments for low testosterone levels in males (“Low–T”). The Company’s point of differentiation, compared to its competitors, is that its drug pipeline (peptides) is not a steroid or a hormone, but is intended to induce the body (specifically, the testes, which is...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: ACSB
• Website: https://acesisbio.com/

Financial Performance

Data Source: SEC filings Last updated: Sep 4, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error